About Zymedi
Zymedi is a company based in Incheon (South Korea) founded in 2019. Zymedi has raised $29.54 million across 2 funding rounds from investors including Industrial Bank of Korea, Company K Partners and UTC Investment. Zymedi offers products and services including ZMA001, ZMP201, ZMC003, and ARS Platform. Zymedi operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Incheon, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.54 M (USD)
in 2 rounds
-
Latest Funding Round
$12.08 M (USD), Series A
May 30, 2023
-
Investors
Industrial Bank of Korea
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zymedi
Zymedi offers a comprehensive portfolio of products and services, including ZMA001, ZMP201, ZMC003, and ARS Platform.
Targets pulmonary arterial hypertension for precision medicine applications.
Vaccine candidate for immune-related disorders treatment.
Drug for neurological diseases addressing unmet needs.
Enables development of first-in-class drugs for hard-to-treat conditions.
Funding Insights of Zymedi
Zymedi has successfully raised a total of $29.54M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.08 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zymedi
Zymedi has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Industrial Bank of Korea, Company K Partners and UTC Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in tech startups
|
Locked | Locked | Locked | |
|
Venture capital and private equity investment firm
|
Locked | Locked | Locked | |
|
Venture capital investments are managed to support startup ecosystems.
|
Locked | Locked | Locked |
Investor details for Zymedi
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zymedi
Investment portfolio details for Zymedi
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zymedi
Detailed financials for Zymedi
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zymedi Comparisons
Peer comparison for Zymedi
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zymedi
Zymedi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for metabolic disorders are developed.
|
|
| Locked | Locked | Locked |
Antibodies for cancer and infectious disease treatments are developed.
|
Detailed competitors of Zymedi
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zymedi
Complete news archive for Zymedi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zymedi
Zymedi was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Zymedi is headquartered in Incheon, South Korea.
Nam Hoon Kwon is the current CEO of Zymedi.
Zymedi is a funded company, having raised a total of $29.54M across 2 funding rounds to date.
Zymedi was founded in 2019 and is based in Incheon, South Korea. Operations focus on the biotechnology sector, where therapeutics for various diseases are developed. Aminoacyl-tRNA Synthetase-based drugs form the core pipeline, including ZM-A001 targeted at pulmonary arterial hypertension, ZM-C001 for non-alcoholic steatohepatitis, and ZM-C101 for colorectal cancer. Leadership is provided by CEO Nam Hoon Kwon.
Zymedi's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
Zymedi offers ZMA001, ZMP201, ZMC003, and ARS Platform.
Zymedi has 7 investors. Key investors include Industrial Bank of Korea, Company K Partners, UTC Investment, Korea Venture Investment Corp, and Medytox Venture.